Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Optison: Marketed for endocardial border delineation and left ventricular opacification

MBIO said that data from two trials showed that Optison allowed

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE